BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Z, Wang Y, Yu Q, Wang S, Kong D. Efficacy of Endoscopic Intervention plus Growth Inhibitor and Patient Self-Management in the Treatment of Esophagogastric Variceal Bleeding in Cirrhosis. Evid Based Complement Alternat Med 2022;2022:6837791. [PMID: 35754688 DOI: 10.1155/2022/6837791] [Reference Citation Analysis]
2 Bernatz S, Weitkamp I, Scholtz J, Koch V, Grünewald LD, Mader C, Ackermann J, Albrecht MH, Martin SS, Vogl TJ, Mahmoudi S. Quantitative analysis of in-TIPS thrombosis in abdominal CT. European Journal of Radiology Open 2022;9:100405. [DOI: 10.1016/j.ejro.2022.100405] [Reference Citation Analysis]
3 Tai Y, Zhao C, Zhang L, Tang S, Jia X, Tong H, Liu R, Tang C, Gao J. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress. J Cell Mol Med 2021;25:10389-402. [PMID: 34609050 DOI: 10.1111/jcmm.16968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Marynissen H, Lodeweyckx T, Bielen D, de Hoon J. Doppler ultrasound to assess the pharmacodynamic effects of splanchnic vasoactive compounds. Br J Clin Pharmacol 2021. [PMID: 34558102 DOI: 10.1111/bcp.15095] [Reference Citation Analysis]
5 Kalra S, Bhattacharya S, Rawal P. Hepatocrinology. Med Sci (Basel) 2021;9:39. [PMID: 34205986 DOI: 10.3390/medsci9020039] [Reference Citation Analysis]
6 Elbahr O, Kamal A, Alsebaey A, Amin M, Abbasy M, Edris A, Nada A, Sabry A, Afiffy S, Helal AE, Abd El-aziz M, Gad-allah AE. Self-expandable metallic stents (SEMS) in esophageal varices post-band ulcer refractory bleeding: a retrospective study. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00100-z] [Reference Citation Analysis]
7 Yu B, Mamedov R, Fuhler GM, Peppelenbosch MP. Drug Discovery in Liver Disease Using Kinome Profiling. Int J Mol Sci 2021;22:2623. [PMID: 33807722 DOI: 10.3390/ijms22052623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Henkel S, Vetterly C, Squires R, McKiernan P, Squires J. Pharmacological management of portal hypertension and its complications in children: lessons from adults and opportunities for the future. Expert Opin Pharmacother 2021;22:291-304. [PMID: 33074032 DOI: 10.1080/14656566.2020.1825685] [Reference Citation Analysis]